Currently, there are 197.85M common shares owned by the public and among those 195.89M shares have been available to trade.
The company’s stock has a 5-day price change of -12.43% and -53.59% over the past three months. ESPR shares are trading -29.55% year to date (YTD), with the 12-month market performance down to -32.02% lower. It has a 12-month low price of $1.56 and touched a high of $3.94 over the same period. ESPR has an average intraday trading volume of 5.01 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.95%, -20.34%, and -27.93% respectively.
Institutional ownership of Esperion Therapeutics Inc (NASDAQ: ESPR) shares accounts for 65.75% of the company’s 197.85M shares outstanding.
It has a market capitalization of $306.67M and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.40% over the week and 6.70% over the month.
Earnings per share for the fiscal year are expected to increase by 82.14%, and -196.62% over the next financial year.
Looking at the support for the ESPR, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on December 18, 2024, with the firm’s price target at $4. Cantor Fitzgerald coverage for the Esperion Therapeutics Inc (ESPR) stock in a research note released on December 17, 2024 offered a Overweight rating with a price target of $8. JP Morgan on their part issued Neutral rating on November 20, 2023.
